ADVA
5.7.2022 09:02:07 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that POST Luxembourg has deployed ADVA’s Oscilloquartz optical cesium atomic clock to protect its GNSS-based timing network from jamming and spoofing cyberattacks. The country’s leading provider of ICT and telecom services is utilizing the aPNT+™ technology to meet the synchronization requirements of 5G mobile connectivity and next-generation enterprise cloud applications. With its high availability and unrivaled holdover, the optical cesium atomic clock solution ensures the accuracy and stability needed for the most stringent telecom applications. The solution integrated easily into POST Luxembourg’s existing network management system and is remotely controlled and assured by the ADVA Ensemble Controller with Sync Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005303/en/
“With this deployment, we’re injecting new levels of precision, stability, resiliency and holdover into our synchronization network. It’s an important step as we look to meet stricter timing requirements driven by emerging applications. ADVA’s Oscilloquartz optical cesium atomic clock empowers us to support our enterprise customers as they harness new industry digitalization opportunities. It’s also a key tool as we move into the next phase of 5G mobile provision,” said Pierre Scholtes, head of telecom networks, POST Luxembourg. “In recent years, we’ve developed a very strong relationship with ADVA’s team. When it came to enhancing and protecting our timing infrastructure for the future, that mutual trust and close support was just as important as the capabilities and performance of ADVA’s technology.”
ADVA’s coreSync OSA 3350 ePRC+™ is now enabling POST Luxembourg to outperform even the most stringent recommendations for the precision and stability of frequency, phase and time. Deployed in the core of the service provider’s timing network, it’s the ideal backup for satellite-based synchronization and the best defense against GNSS jamming and spoofing attacks. The coreSync OSA 3350 ePRC+™ is the first commercial optical cesium atomic clock specifically designed for ePRC applications that require outstanding stability and resiliency. It offers enhanced holdover compared with standard magnetic cesium clocks. When combined with an OSA grandmaster clock combiner solution to create an enhanced primary reference time clock (ePRTC) system, it provides holdover stability under 35ns for more than 14 days. This is significantly better than the ITU ePRTC specification, which requires no more than 70ns from UTC after a 14-day period.
“Our market-first optical cesium atomic clock is now delivering phenomenal holdover and protecting timing integrity throughout POST Luxembourg’s network. For customers across the Benelux region, it opens the door to a world of new applications that require extremely high reliability as well as very low latency,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Complementing satellite-based synchronization solutions with ultra-stable atomic clocks is the best available way to safeguard against GNSS vulnerabilities and meet new requirements for precision and availability. POST Luxembourg is once again leading the way in Europe by adopting the most advanced innovation so it can continue to outperform customer expectations.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
